Home › Squamous Cell Carcinoma ng Ulo at Leeg › California › San Diego
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa San Diego, CA
14 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng San Diego (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi ang layo
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Nagre-recruitPhase 2/3
- Site #0107, La Jolla · 11 mi ang layo
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Nagre-recruitPhase 1
- ALX Center 9, La Jolla · 11 mi ang layo
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Nagre-recruitPhase 3
- Scripps Health, La Jolla · 11 mi ang layo
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Nagre-recruitPhase 3
- University of California at San Diego Moores Cancer Center, La Jolla · 11 mi ang layo
Intratumoral N17350 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Scripps Clinic Torrey Pines - La Jolla, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Nagre-recruitObservasyonal na pag-aaral
- University of California, San Diego, La Jolla · 11 mi ang layo
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi ang layo
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Nagre-recruitPhase 2/3
- UC San Diego Medical Center - Hillcrest, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi ang layo
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Nagre-recruitPhase 2
- UC San Diego Medical Center - Hillcrest, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi ang layo
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sharp Healthcare, San Diego
- UCSD, La Jolla · 11 mi ang layo
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Nagre-recruitPhase 1/2
- UCSD Moores Cancer Center, La Jolla · 11 mi ang layo
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Nagre-recruitPhase 1
- Moores Cancer Center UC San Diego Health, La Jolla · 11 mi ang layo
A Beta-only IL-2 ImmunoTherapY Study
Nagre-recruitPhase 1/2
- Sharp Memorial Hospital, San Diego
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Philadelphia, PA26 pag-aaral
- Chicago, IL26 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- New Haven, CT22 pag-aaral
Iba pang pag-aaral sa San Diego
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser sa Suso41 pag-aaral
- Kanser (lahat ng uri)32 pag-aaral
- Kanser sa Prostate31 pag-aaral
- Metastatic Cancer30 pag-aaral
- Colorectal Cancer25 pag-aaral
- Kanser sa Ovary24 pag-aaral
- Kanser sa Pancreas24 pag-aaral
- Kanser sa Baga23 pag-aaral
- Obesity23 pag-aaral
- Pagkabigo ng Puso23 pag-aaral
- Depression21 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.